ABC/3TC/ZDV (N = 138) | ATV+3TC/ZDV (N = 140) | |
---|---|---|
Virologic Responders | 120 (87%) | 123 (88%) |
Protocol-Defined Virologic Failures | 18 (13%) | 17 (12%) |
1. Less than 1 log10 reduction in baseline plasma HIV-1 RNA by week 12 | 3 | 3 |
2. Reduction of plasma HIV-1 RNA < 50 copies/mL on two occasions with a subsequent increase to ≥ 400 copies/mL on two consecutive occasions prior to week 24 | 2 | 2 |
3. Failure to achieve plasma HIV-1 RNA < 400 copies/mL by Week 24 | 3 | 4 |
4. Plasma HIV-1 RNA ≥ 400 copies/mL on consecutive occasions after Week 24 | 6 | 11 |
5. Plasma HIV-1 RNA ≥ 400 copies/mL at Week 48 without confirmation | 7 | 3 |
Subjects meeting multiple virologic failure criteria 1 | 3 | 5 |
Post-Baseline Genotype and Phenotype | 17 | 16 |
Subjects with treatment-emergent mutations | 10 | 11 |
Any NRTI-associated Mutations 2 | 8 | 9 |
(M184V, M184M/V, L74V, L74I/V D67N, L210W) | ||
Any PI-associated mutations | 7 | 6 |
(G16E, K20M, L24I, L33V, I54I/L, I62V, V77I, I85I/V, I93I/L) | ||
Any NNRTI-associated mutations | 0 | 1 |
(K103N) |